Stock Market & Financial Investment News

Revance risk not heightened from FDA guidance, says Piper Jaffray Piper Jaffray does not see heightened risk around Revance's RT001 after the FDA issued draft guidance on clinical endpoints for botulinum toxin products for the treatment of upper facial lines. The firm reiterates an Overweight rating on the stock with a $44 price target.